Budget Impact Analysis of Panobinostat – Bortezomib and Dexamethasone, As 3rd Or 4th Line of Treatment in Patients with Relapsed/Refractory Multiple Myeloma in Greece

Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.2189
https://www.valueinhealthjournal.com/article/S1098-3015(16)33555-0/fulltext
Section Title : Disease-Specific Studies
Section Order : 2078
First Page : A729
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33555-0&doi=10.1016/j.jval.2016.09.2189
HEOR Topics :
Tags :
Regions :